Indications for TYMLOS:
Postmenopausal women with osteoporosis at high risk for fracture.
Limitations of Use:
Cumulative use >2yrs not recommended.
80mcg SC once daily into periumbilical region of abdomen; rotate inj sites. Give supplemental calcium and vitamin D if dietary intake inadequate.
Risk of osteosarcoma.
Increased baseline risk for osteosarcoma (eg, Paget's disease of bone, unexplained increased alkaline phosphatase, open epiphyses, bone metastases or skeletal malignancies, hereditary disorders predisposing to osteosarcoma, prior external beam or skeletal implant radiation therapy), pre-existing hypercalcemia or underlying hypercalcemic disorder (eg, primary hyperparathyroidism): not recommended. Urolithiasis. Hypercalciuria. Severe renal impairment: monitor. Pregnancy, nursing mothers: not indicated.
Hormone (human parathyroid hormone related peptide analog).
Hypercalciuria, dizziness, nausea, headache, palpitations, fatigue, upper abdominal pain, vertigo; orthostatic hypotension, hypercalcemia, urolithiasis, inj site reactions.
Prefilled pen (1.56mL)—1